TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i
 
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:Acacia Pharma Group plc
1b. Please indicate if the issuer is a non-UK issuer  (please mark with an “X” if appropriate)
Non-UK issuer 
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rightsX
An acquisition or disposal of financial instruments 
An event changing the breakdown of voting rights 
Other (please specify)iii: 
3. Details of person subject to the notification obligationiv
NameThe Novo Nordisk Foundation
City and country of registered office (if applicable)Tuborg Havnevej 19, 2900 Hellerup, Denmark
4. Full name of shareholder(s) (if different from 3.)v
NameNovo Holdings A/S
City and country of registered office (if applicable)Tuborg Havnevej 19, 2900 Hellerup, Denmark
5. Date on which the threshold was crossed or reachedvi:5 September 2019
6. Date on which issuer notified (DD/MM/YYYY):6 September 2019
7. Total positions of person(s) subject to the notification obligation
 % of voting rights attached to shares (total of 8. A)% of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B)Total number of voting rights of issuervii
Resulting situation on the date on which threshold was crossed or reached6.92% 6.92%53,442,417
Position of previous notification (if
applicable)
7.98% 7.98%53,335,420



9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii 
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)
X
Namexv% of voting rights if it equals or is higher than the notifiable threshold% of voting rights through financial instruments if it equals or is higher than the notifiable thresholdTotal of both if it equals or is higher than the notifiable threshold
The Novo Nordisk Foundation6.92%  
Novo Holdings A/S6.92%  
    
    
    
 
10. In case of proxy voting, please identify:
Name of the proxy holder 
The number and % of voting rights held 
The date until which the voting rights will be held 
 
11. Additional informationxvi
The shares are held by Novo Holdings A/S, the holding company in the Novo Group. Novo Holdings A/S is wholly-owned by the Novo Nordisk Foundation.


Place of completionHellerup, Denmark
Date of completion6 September 2019